Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Initial treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma in the era of BTK inhibitors: A multicenter real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDepei WuTYTao YouJZJin Zhou

Discussion

Loading...

Member takes

Overview

Multicenter study finds first-line BTK inhibitors improve overall survival in mantle cell lymphoma patients, indicating their clinical importance.

Key Points

  • The aim was to characterize treatment approaches and survival outcomes in mantle cell lymphoma patients.
  • Retrospective analysis of 234 patients from four major hematology centers in China
  • Evaluation of treatment patterns and outcomes from 2017 to 2025
  • Inclusion of survival statistics and prognostic factor assessments.
  • 93.6% received Rituximab as first-line therapy
  • 1-year overall survival rate was 90.2%, with 2-year at 82.7%
  • Use of BTK inhibitors showed borderline significance in improving 2-year overall survival rates.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d1fbhttps://doi.org/10.1182/blood-2025-7100
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world Evidence of Treatment Outcomes in Mantle Cell Lymphoma: A Single-center Experience in Southern Taiwan2026
  2. 2Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study2025 · 1 citations
  3. 3Emerging first-line treatment approaches for mantle cell lymphoma2025
  4. 4Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?2026 · 1 citations
  5. 5Real-world treatment and safety outcomes of patients with Mantle Cell Lymphoma in the United States2025